Last Updated: November 16, 2026

Investigational Drug Information for Foliglurax

« Back to Dashboard


What is the drug development status for Foliglurax?

Foliglurax is an investigational drug.

There have been 6 clinical trials for Foliglurax. The most recent clinical trial was a Phase 2 trial, which was initiated on January 15th 2018.

The most common disease conditions in clinical trials are Parkinson Disease, Dyskinesias, and [disabled in preview]. The leading clinical trial sponsors are H. Lundbeck A/S, Prexton Therapeutics, and [disabled in preview].

There are fourteen US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for Foliglurax
TitleSponsorPhase
Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy SubjectsH. Lundbeck A/SPhase 1
Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy SubjectsH. Lundbeck A/SPhase 1
Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)H. Lundbeck A/SPhase 1

See all Foliglurax clinical trials

Clinical Trial Summary for Foliglurax

Top disease conditions for Foliglurax
Top clinical trial sponsors for Foliglurax

See all Foliglurax clinical trials

US Patents for Foliglurax

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Foliglurax ⤷  Start Trial Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors Prexton Therapeutics SA ⤷  Start Trial
Foliglurax ⤷  Start Trial Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors Prexton Therapeutics SA ⤷  Start Trial
Foliglurax ⤷  Start Trial Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia Prexton Therapeutics SA ⤷  Start Trial
Foliglurax ⤷  Start Trial Composition and method for treating neurological disease Adamas Pharmaceuticals Inc ⤷  Start Trial
Foliglurax ⤷  Start Trial Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid H Lundbeck AS ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Foliglurax

Drugname Country Document Number Estimated Expiration Related US Patent
Foliglurax Australia AU2015308438 2034-08-27 ⤷  Start Trial
Foliglurax Australia AU2016313138 2034-08-27 ⤷  Start Trial
Foliglurax Canada CA2956191 2034-08-27 ⤷  Start Trial
Foliglurax Canada CA2995313 2034-08-27 ⤷  Start Trial
Foliglurax Chile CL2018000497 2034-08-27 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.